Related references
Note: Only part of the references are listed.Next-Generation Sequencing Reveals Potential Predictive Biomarkers and Targets of Therapy for Urothelial Carcinoma in Situ of the Urinary Bladder
Stefan Garczyk et al.
AMERICAN JOURNAL OF PATHOLOGY (2020)
Transcriptional Analysis of Immunohistochemically Defined Subgroups of Non-Muscle-Invasive Papillary High-Grade Upper Tract Urothelial Carcinoma
Minsun Jung et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Y. Loriot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype
Jorge Rebola et al.
VIRCHOWS ARCHIV (2019)
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-2019 Update
Marko Babjuk et al.
EUROPEAN UROLOGY (2019)
Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites
Amin H. Nassar et al.
CLINICAL CANCER RESEARCH (2019)
Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma
Minsun Jung et al.
HISTOPATHOLOGY (2019)
Molecular profiling in muscle-invasive bladder cancer: more than the sum of its parts
Gottfrid Sjodahl et al.
JOURNAL OF PATHOLOGY (2019)
Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications
Isabella Barth et al.
VIRCHOWS ARCHIV (2018)
Current Clinical Trials in Non-muscle Invasive Bladder Cancer
Timo K. Nykopp et al.
CURRENT UROLOGY REPORTS (2018)
Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition
George Au-Yeung et al.
CLINICAL CANCER RESEARCH (2017)
Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway
Michelle R. Downes et al.
HISTOPATHOLOGY (2017)
Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets
Eugene J. Pietzak et al.
EUROPEAN UROLOGY (2017)
p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant
Anjelica Hodgson et al.
HISTOPATHOLOGY (2017)
Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2
Lian Dee Ler et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival
Johannes Breyer et al.
VIRCHOWS ARCHIV (2017)
The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer
Shu-Xiong Zeng et al.
CLINICAL CANCER RESEARCH (2017)
Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency
Carolyn D. Hurst et al.
CANCER CELL (2017)
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
A. Gordon Robertson et al.
CELL (2017)
DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma
Min Yuen Teo et al.
CLINICAL CANCER RESEARCH (2017)
Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression
Hideaki Ogiwara et al.
CANCER DISCOVERY (2016)
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
Jakob Hedegaard et al.
CANCER CELL (2016)
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline
Sam S. Chang et al.
JOURNAL OF UROLOGY (2016)
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors
Jianfeng Shen et al.
CANCER DISCOVERY (2015)
Combined CDKN1A/TP53 Mutation in Bladder Cancer Is a Therapeutic Target
Yang Liu et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity
Margaret A. Knowles et al.
NATURE REVIEWS CANCER (2015)
Management of carcinoma in situ of the bladder: best practice and recent developments
Dominic H. Tang et al.
THERAPEUTIC ADVANCES IN UROLOGY (2015)
Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer
Russell Moser et al.
CLINICAL CANCER RESEARCH (2014)
Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
Jeffrey S. Damrauer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Mixed low- and high-grade papillary urothelial carcinoma: histopathogenetic and clinical significance
Kien T. Mai et al.
VIRCHOWS ARCHIV (2013)
CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma
Sandra Rebouissou et al.
JOURNAL OF PATHOLOGY (2012)
Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma
Hikmat A. Al-Ahmadie et al.
JOURNAL OF PATHOLOGY (2011)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer
D. C. Tomlinson et al.
JOURNAL OF PATHOLOGY (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition
Nuala McCabe et al.
CANCER RESEARCH (2006)
The NF1 tumor suppressor critically regulates TSC2 and mTOR
CM Johannessen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?
HW Herr et al.
JOURNAL OF UROLOGY (2001)
Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer:: A direct comparison of fluorescence in situ hybridization and immunohistochemistry
G Pauletti et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome
HW Herr
JOURNAL OF UROLOGY (2000)
Share Paper
